Cargando…

Molecular and Functional Characteristics of Ovarian Surface Epithelial Cells Transformed by KrasG12D and loss of Pten in a Mouse Model in vivo

Ovarian cancer is a complex and deadly disease that remains difficult to detect at an early curable stage. Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive sp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mullany, Lisa K., Fan, Heng-Yu, Liu, Zhilin, White, Lisa D., Marshall, Alexandra, Gunaratne, Preethi, Anderson, Matthew L., Creighton, Chad J., Xin, Li, Deavers, Michael, Wong, Kwong-Kwok, Richards, JoAnne S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139785/ https://www.ncbi.nlm.nih.gov/pubmed/21423204 http://dx.doi.org/10.1038/onc.2011.70

Ejemplares similares

Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors
por: Goebel, Lisa, et al.
Publicado: (2023)

KRasG12C inhibitors in clinical trials: a short historical perspective
por: Goebel, Lisa, et al.
Publicado: (2020)

Role and regulation of Yap in KrasG12D-induced lung cancer
por: Mao, Yaopan, et al.
Publicado: (2017)

Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional KrasG12D mice
por: Xu, Mu, et al.
Publicado: (2018)

Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis
por: Richards, JoAnne S., et al.
Publicado: (2011)

Addition of metabolomics to the omics spectrum for cancer biomarker development– demonstration with the KrasG12D mouse model for pancreatic carcinoma
por: Laiakis, Evagelia C, et al.
Publicado: (2014)

Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice
por: Chang, Hui-Hua, et al.
Publicado: (2017)

Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model
por: Chang, Hui-Hua, et al.
Publicado: (2018)

Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice
por: Teper, Yaroslav, et al.
Publicado: (2023)

Growth Arrest Specific-1 (GAS1) Is a C/EBP Target Gene That Functions in Ovulation and Corpus Luteum Formation in Mice
por: Ren, Yi A., et al.
Publicado: (2016)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival()
por: Mullany, Lisa K., et al.
Publicado: (2015)

HMGA1 expression levels are elevated in pancreatic intraepithelial neoplasia cells in the Ptf1a-Cre; LSL-KrasG12D transgenic mouse model of pancreatic cancer
por: Veite-Schmahl, Michelle J, et al.
Publicado: (2017)

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas
por: Crane, Erin K., et al.
Publicado: (2015)

Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue
por: Chambers, Andrew G., et al.
Publicado: (2023)

NMR-based metabolic profiling of urine, serum, fecal, and pancreatic tissue samples from the Ptf1a-Cre; LSL-KrasG12D transgenic mouse model of pancreatic cancer
por: Schmahl, Michelle J., et al.
Publicado: (2018)

EPHA2-dependent outcompetition of KRASG12D mutant cells by wild-type neighbors in the adult pancreas
por: Hill, William, et al.
Publicado: (2021)

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
por: Macaya, Irati, et al.
Publicado: (2023)

Fibroblast growth factor receptor signaling plays a key role in transformation induced by the TMPRSS2/ERG fusion gene and decreased PTEN
por: Shao, Longjiang, et al.
Publicado: (2018)

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023)

Non-target genetic manipulation induces rhabdomyosarcoma in KrasPten-driven mouse model of ovarian cancer
por: Lai, Huiling, et al.
Publicado: (2020)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

Effects of PTEN Loss and Activated KRAS Overexpression on Mechanical Properties of Breast Epithelial Cells
por: Linthicum, Will, et al.
Publicado: (2018)

KRAS-driven ROS promote malignant transformation
por: Suh, Yongjoon, et al.
Publicado: (2015)

Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial to mesenchymal transition in ovarian cancer
por: Zhang, Lixin, et al.
Publicado: (2016)

Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
por: Chen, Yu, et al.
Publicado: (2015)

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer
por: Mao, Chen, et al.
Publicado: (2012)

A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion
por: Ikenoue, Tsuneo, et al.
Publicado: (2016)

Can Nimesulide Nanoparticles Be a Therapeutic Strategy for the Inhibition of the KRAS/PTEN Signaling Pathway in Pancreatic Cancer?
por: Ferreira, Roseane Guimarães, et al.
Publicado: (2021)

Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
por: Ciardiello, D., et al.
Publicado: (2022)

Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma
por: Duman, Berna B., et al.
Publicado: (2014)

Corrigendum: A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion
por: Ikenoue, Tsuneo, et al.
Publicado: (2017)

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients
por: Lu, Hong-Yang, et al.
Publicado: (2018)

Characterization of rare transforming KRAS mutations in sporadic colorectal cancer
por: Tong, Joanna HM, et al.
Publicado: (2014)

Using Effective Subnetworks to Predict Selected Properties of Gene Networks
por: Gunaratne, Gemunu H., et al.
Publicado: (2010)

Loss of Canonical Smad4 Signaling Promotes KRAS Driven Malignant Transformation of Human Pancreatic Duct Epithelial Cells and Metastasis
por: Leung, Lisa, et al.
Publicado: (2013)

P53 Gain-of-Function Mutants and Steroids in Ovarian Cancer Cell Metastasis
por: Candelaria, Nicholes, et al.
Publicado: (2021)

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells
por: Padmanabhan, Achuth, et al.
Publicado: (2018)

Aurora kinase targeting in lung cancer reduces KRAS-induced transformation
por: dos Santos, Edmilson Ozorio, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lqsph98fv2ncifa3u5je459k6l